 Catalyst Biosciences is targeting the hemophilia space with a strong candidate treating types A and B with inhibitors, and second targeting type B. Current standard of care NovoSeven is administered intravenously, whilst Catalysts candidates can be administered subcutaneously - a key advantage. 